期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Downregulation of serum mi R-17 and mi R-106b levels in gastric cancer and benign gastric diseases 被引量:12
1
作者 Qinghai Zeng Cuihong Jin +11 位作者 Wenhang Chen Fang Xia Qi Wang Fan Fan Juan Du Yihang Guo Changwei Lin Kaiyan Yang Jingjing Li Xiaowei Peng Xiaorong Li Ke Cao 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2014年第6期711-716,共6页
Altered micro RNA(mi RNA) associated with gastric cancer(GC) development and mi R-17 and mi R-106 b were differentially expressed in GC tissues. This study detected serum levels of mi R-17 and mi R-106 b expressio... Altered micro RNA(mi RNA) associated with gastric cancer(GC) development and mi R-17 and mi R-106 b were differentially expressed in GC tissues. This study detected serum levels of mi R-17 and mi R-106 b expression in GC, benign gastric disease(BGD) and healthy controls to assess them as tumor markers for GC. Serum samples from 40 GC, 32 BGD(10 gastric ulcer, 14 gastric polyps, and 8 gastric ulcer with polyps) and 36 healthy individuals were subjected to quantitative reverse transcription polymerase chain reaction(q RT-PCR) analysis of mi R-17 and mi R-106 b expression. The data showed that the serum levels of mi R-17 and mi R-106 b were significantly reduced in healthy individuals and BGD patients compared to GC patients. There was a significant association of mi R-17 and mi R-106 b expression with age, but not with other clinicopathological features, such as gender, tumor differentiation, stage and lymphatic metastasis. Further analysis showed that, in discriminating GC patients from healthy controls, mi R-17 could yield a receiver-operating characteristic(ROC) area under the curve(AUC) of 0.879 with 80.6% sensitivity and 87.5% specificity and mi R-106 b could yield an AUC of 0.856 with 75.0% sensitivity and 92.5% specificity. The combined AUC of mi R-17 and mi R-106 b was 0.913 with 83.3% sensitivity and 87.5% specificity. Collectively, these data suggest that detection of serum mi R-17 and mi R-106 b levels should be further evaluated as novel non-invasive biomarkers in early GC detection and surveillance of disease progression. 展开更多
关键词 miR-17 miR-106b gastric cancer(GC) benign gastric disease(BGD) biomarker
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部